Community Practice Connections™: 25th Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and Myeloma

Release Date: May 17, 2021
Expiration Date: May 17, 2022

Activity Overview

Community Practice Connections™: 25th Annual International Congress on Hematologic Malignancies^®: Focus on Leukemias, Lymphomas, and Myeloma consists of a series of interactive clinical vignettes, short video interviews with leading experts in hematologic malignancies, and short summaries of clinical data related to these issues. The video interviews address decision points in the clinical vignettes and questions commonly faced in the community oncology practice setting.

Acknowledgement of Commercial Support

This activity is supported by educational grants from AbbVie Inc; Astellas Pharma Inc; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo, Inc; Genentech, Inc; Genmab US, Inc; Gilead Sciences, Inc; Jazz Pharmaceuticals, Inc; Kite Pharma, Inc; Legend Biotech USA, Inc; Lilly; Novartis Pharmaceuticals Corporation; Pfizer Inc; Rigel Pharmaceuticals; Sanofi Genzyme; Seagen Inc (formerly Seattle Genetics, Inc); Syndax Pharmaceuticals, Inc; and Takeda Oncology.

For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.

Target Audience

This educational activity is directed toward community-based hematologists and medical oncologists, as well as fellows involved in the treatment and management of hematologic malignancies. Nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies may also participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Assess current and emerging biomarkers to determine risk and choose therapy for patients with hematologic malignancies
• Integrate key clinical data on current treatment approaches for the management of hematologic malignancies and benign hematologic disorders
• Discuss recent clinical trial results on emerging therapeutic approaches for patients with hematologic malignancies
• Describe approaches to mitigate and manage treatment-related adverse events in patients with hematologic malignancies
• Evaluate clinical implications of evolving therapeutic paradigms in hematologic malignancies

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Sagar Lonial, MD, FACP
Professor and Chair, Department of Hematology
and Medical Oncology
Emory University School of Medicine
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, GA

Disclosures: Consultant: Bristol Myers Squibb, Celgene Corporation, Janssen Pharmaceutical Companies of Johnson & Johnson, Merck, Millennium Pharmaceuticals Inc, Novartis, Onyx Enterprises Int’l Corp, Sanofi.

Jorge E. Cortes, MD
Director, Georgia Cancer Center
GRA/Whitaker Eminent Scholar in Cancer
Georgia Research Alliance
Augusta University
Augusta, GA

Disclosures: Grant/Research Support: Bristol Myers Squibb, Novartis, Pfizer Inc, Sun Pharmaceutical Industries Ltd, Takeda; Consultant: Bristol Myers Squibb, Novartis, Pfizer Inc, Takeda.

Jennifer Brown, MD, PhD
Professor of Medicine
Harvard Medical School
Director, Chronic Lymphocytic Leukemia Center
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Grant/Research Support: Gilead Sciences, Loxo Oncology, Sun Pharmaceutical Industries Ltd, TG Therapeutics, Verastem Oncology; Consultant: AbbVie, Acerta Pharma, AstraZeneca, BeiGene, Bristol Myers Squibb/Juno/Celgene Therapeutics, Catapult Therapeutics, Eli Lilly and Company, Genentech/Roche, MEI Pharma, Nextcea Inc, Novartis, Pfizer, Rigel Pharmaceuticals; Other: Invectys (Data and Safety Monitoring Committee Service).

Lori Leslie, MD
Director, Indolent Lymphoma and Chronic Lymphocytic Leukemia Research Programs
John Theurer Cancer Center
Hackensack University Medical Center
Hackensack, NJ

Disclosures: Consultant: AbbVie, ADC Therapeutics, AstraZeneca, Bayer Healthcare, Celgene Corporation/Bristol Myers Squibb, Genentech, Janssen Pharmaceuticals, Kite Pharma, Pharmacyclics, Seattle Genetics; Speakers Bureau: AstraZeneca, BeiGene, Celgene Corporation/Bristol Myers Squibb, Kite Pharma, Pharmacyclics/Janssen Pharmaceutical, Seattle Genetics.

Corey Cutler, MD, MPH, FRCPC
Associate Professor of Medicine
Harvard Medical School
Medical Director, Adult Stem Cell Transplantation
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Consultant: Elsalys Biotech, Genentech, Incyte Corporation, Janssen, Jazz Pharmaceuticals, Medsenic, Omeros, Syndax.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.